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Original Article
Aim: Coronary artery disease (CAD) and cognitive impairment are common in the elderly, with evidence for 
shared risk factors and pathophysiological processes. The coronary artery calcium (CAC) score is a marker of 
subclinical CAD, which may allow early detection of individuals prone to cognitive decline. Prior studies on 
associations of CAC and clinical CAD with cognitive impairment had discrepant results. This systematic review 
aims to evaluate the association of (sub)clinical CAD with cognitive function, cognitive decline, and diagnosis of 
mild cognitive impairment (MCI) or dementia.
Methods: A systematic search was conducted in MEDLINE, Embase, and Web of Science until February 2019, 
supplemented with citations tracking. Two reviewers independently screened studies and extracted information 
including odds ratios (ORs) and hazard ratios (HRs).
Results: Forty-six studies, 10 on CAC and 36 on clinical CAD, comprising 1,248,908 participants were 
included in the systematic review. Studies about associations of (sub)clinical CAD with cognitive function and 
cognitive decline had heterogeneous methodology and inconsistent findings. Two population-based studies 
investigated the association between CAC and risk of dementia over 6–12.2 years using different CAC scoring 
methods. Both found a tendency toward higher risk of dementia as CAC severity increased. Meta-analysis in 15 
studies (663,250 individuals) showed an association between CAD and MCI/dementia (pooled OR 1.32, 95%CI 
1.17–1.48) with substantial heterogeneity (I2=87.0%, p＜0.001). Pooled HR of CAD for incident MCI/demen-
tia over 3.2–25.5 years in six longitudinal studies (70,060 individuals) was 1.51 (95%CI 1.24–1.85), with low 
heterogeneity (I2=14.1%, p=0.32). Sensitivity analysis did not detect any study that was of particular influence 
on the pooled OR or HR.
Conclusions: Limited evidence suggests the CAC score is associated with risk of dementia. In clinical CAD, 
risk of MCI and dementia is increased by 50%, as supported by stronger evidence.
of CAD has declined during the past decades because 
of improvement in disease management, resulting in 
an increasing number of CAD patients with a higher 
life expectancy1). These patients, although they survive 
CAD, may develop other age-related diseases such as 
dementia in their late life. Mild cognitive impairment 
Introduction 
Coronary artery disease (CAD) and dementia are 
common in the elderly. The prevalence of CAD and 
dementia is estimated to be 14.9% and 5.2%, respec-
tively, among adults over 60 years of age1, 2). Mortality 
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with the Meta-analysis of Observational Studies in 
Epidemiology (MOOSE) statement20) and Preferred 
Reporting Items for Systematic reviews and Meta-
Analysis (PRISMA) statement21).
Search Strategy
MEDLINE, Embase, and Web of Science were 
searched from inception to February 2019 without 
limits on publication dates. The search strategy 
included terms relevant to coronary atherosclerosis 
and cognitive impairment (see Supplementary Table 
1). Additional appropriate articles were manually 
added when discovered by tracking citations. An expe-
rienced medical information expert checked the search 
strategy.
Selection Criteria
The following inclusion criteria were used to 
determine eligibility of a study: (1) all types of studies 
that examined both coronary atherosclerosis and cog-
nitive function regardless of the study design con-
cerned, that is, cross-sectional, case–control, or longi-
tudinal cohorts (≥ 1 year follow-up); (2) coronary ath-
erosclerosis as defined by clinical CAD events or by 
subclinical CAD as quantified by CAC scoring; (3) 
cognitive function based on either validated mental 
state examinations and neuropsychological testing or 
clinically diagnosed MCI or dementia; and (4) study 
sample size larger than 100.
Invasive interventions for CAD may have a nega-
tive effect on subsequent cognitive performance14). In 
addition, the effect of CAD on cognition may be dis-
torted by atrial fibrillation, stroke, or heart failure 
because of different underlying pathophysiological 
mechanisms22). Therefore, we excluded studies (1) that 
clearly mentioned that participants had undergone 
invasive cardiac procedures prior to cognitive function 
testing; (2) that did not consider invasive intervention 
as a confounder for statistical analysis; and (3) that 
solely focused on patients with atrial fibrillation, 
stroke, or heart failure. We also excluded case reports, 
reviews, conference abstracts, editorials, or articles not 
published in English. In case of multiple articles that 
reported results based on the same cohort, we only 
included those articles that reported the largest sample 
size or that best addressed our research question.
(MCI) is an intermediate stage between age-related 
cognitive decline and clinically diagnosed dementia 
and may be a prodromal stage of Alzheimer’s disease 
(AD) or other neurodegenerative disorders3). Poten-
tially, early detection of MCI/dementia combined 
with preventive intervention could delay the progres-
sion to dementia. It is important to research the rela-
tionship between CAD and MCI/dementia in view of 
the possibility of measures to prevent dementia in 
CAD patients.
Epidemiological studies have shown that vascular 
risk factors are associated with cognitive decline and 
with incidence of MCI and dementia including AD4, 5). 
There is evidence for shared pathophysiological mech-
anisms between cardiovascular disease and dementia: 
vascular risk factors and heart diseases might contrib-
ute to MCI and dementia through pathways including 
neurodegeneration, cerebral atherosclerosis, and cere-
bral hypoperfusion and hypoxia6). Vascular pathology 
such as intracranial atherosclerosis can convert low-
grade AD to overt dementia7). Reviews and meta-
analysis have found cardiovascular diseases such as 
atrial fibrillation and heart failure to be associated 
with increased risk of dementia8, 9). However, so far, 
results on associations between clinical CAD and the 
risk of cognitive decline are inconsistent10-13). Caution 
is needed when summarizing evidence from longitudi-
nal studies linking CAD to dementia; particularly, 
estimated effects may be distorted by study popula-
tions with prior invasive intervention14).
There is increasing interest to use coronary artery 
calcium (CAC) scoring as imaging biomarker for sub-
clinical CAD to estimate cardiovascular disease risk15, 16). 
Also, in population-based studies on calcium scoring, 
discrepant results on the relationship of CAC  with 
cognitive function decline were found17-19). So far, 
there has been no systematic review of associations 
between CAC and cognitive impairment.
The aim of the current study was to systemati-
cally review the literature on the association of (sub)
clinical CAD with cognitive function. To meet this 
aim, we addressed the following question: What is the 
association of CAC and clinical CAD with (1) cogni-
tive function, (2) cognitive decline, and (3) risk of 
MCI or dementia?
Methods
This systematic review was performed in line 
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detect any study that may be influential in the overall 
estimated effect. To explore potential source of hetero-
geneity across the studies, subgroup analysis was per-
formed on the basis of study design. Statistical analysis 
was conducted using R (Package “meta,” R Founda-
tion, Vienna, Austria). A two-tailed value of p＜0.05 




The results of the search strategy and selection 
process are shown in Fig.1. After removal of dupli-
cates, 6,601 studies were screened on the basis of title 
and abstract. Finally, 46 studies (10 for CAC, 36 for 
clinical CAD), comprising 1,248,908 participants, 
were included for the systematic review. The main 
study characteristics are provided in Supplementary 
Tables 2 and 3. The main results of the studies are 
shown in Supplementary Tables 4 and 5, sorted by 
outcome: cognitive function, changes of cognitive 
function over time, and risk of MCI/dementia. Qual-
ity of studies that investigated the association between 
clinical CAD and diagnosis of MCI/dementia was 
variable (Supplementary Tables 6–8). Ten studies on 
clinical CAD had suboptimal ascertainment of expo-
sure as determination of clinical CAD was self-
reported or not described11, 25-33). 
Coronary Artery Calcium Score and Cognitive 
Function 
Association with Cognitive Function
Three cross-sectional studies17, 34, 35) and two lon-
gitudinal cohort studies36, 37) examined the cross-sec-
tional association between CAC and cognitive scores 
for different cognitive domains. Increasing severity of 
CAC was associated with worse performance of epi-
sodic memory34, 36), semantic fluency36), executive 
function17, 34-36), and global cognition34, 37).
Association with Cognitive Decline
One study examined the association between 
CAC and deterioration of cognitive function over 18 
years of follow-up in patients with type 1 diabetes (n=  
1,045). There was no difference in mean change of 
cognitive scores between diabetes patients with and 
without CAC38).
Association with cognitive impairment or dementia
Four longitudinal studies reported the associa-
tion between increased CAC at baseline and clinically 
relevant cognitive impairment or dementia18, 19, 39, 40). 
The Rotterdam study in the elderly (n=2,326) showed 
Study Selection, Data Collection, and Quality 
Assessment
Two reviewers (C.X. and M.V.) independently 
performed the selection process and data extraction of 
included studies. Articles were first evaluated for eligi-
bility on the basis of the selection criteria. A standard-
ized data extraction form was used to collect the fol-
lowing information for eligible articles: publication 
details, study population characteristics, study setting, 
CAC measurements, determination of CAD and cog-
nitive function, and description of results. Studies 
included for meta-analysis were evaluated for study 
quality. For observational studies including cohort and 
case–control studies, the Newcastle–Ottawa Scale 
(NOS) was used for the quality assessment23), whereas 
for cross-sectional studies, an adapted NOS version 
was used24). In case of a disagreement in article selec-
tion or data extraction, this was discussed between the 
two reviewers and consensus was obtained, or a third 
reviewer (R.V.) was consulted.
Data Analysis
This systematic review evaluates the relationship 
of CAC score and clinical CAD with cognitive func-
tion. For each part, the following three questions were 
evaluated: the association of CAC score or clinical 
CAD with (1) cognitive function, (2) changes of cog-
nitive function over time/cognitive decline, and (3) 
risk of MCI or dementia. The strength of associations 
between CAC score or clinical CAD and MCI or 
dementia as dichotomous outcomes was estimated 
using either odds ratio (OR) or hazard ratio (HR) and 
95% confident intervals (CIs). Meta-analysis was con-
ducted if there were at least two studies that reported 
the same outcome of interest (MCI and/or dementia). 
If studies reported the results of myocardial infarction 
(MI) and angina pectoris (AP) separately, then only 
the results of the MI were used in this systematic 
review, and the AP results were excluded since MI is a 
harder endpoint of CAD. OR and HR (derived from 
a multivariable model in each study if available) were 
pooled separately using the inverse variance method 
with DerSimonian–Laird random-effects model 
despite inter-study heterogeneity. Pooled estimated 
effect was tested using the Z test. Heterogeneity was 
assessed using the Q statistic test and I2 statistic. A 
two-tailed p value for Q statistic ＜0.10 and I2 ＞50% 
was considered to indicate heterogeneity. Reporting 
biases or small-study effects were evaluated by visual 
evaluation of the funnel plot of each pooling analysis 
for symmetry. Egger’s test for funnel plot asymmetry 
was performed only if the number of studies for pool-
ing analysis was sufficient (≥ 10). Sensitivity analysis 
was conducted using the leave-one-out method to 
Advance Publication Journal of Atherosclerosis and Thrombosis 
Accepted for publication: November 18, 2019    Published online: February 15, 2020
Xia et al.
4
patients (n=148) found significantly elevated risk of 
MCI with increasing CAC score categories after 14 
years39).
Clinical Coronary Artery Disease and Cognitive 
Function
Association with Cognitive Function
Seven studies reported the association between 
clinical CAD and cognitive function41-47). Specifically, 
three cross-sectional studies (n=516–478,557) found 
that presence of CAD was associated with poorer cog-
nitive scores in the domain of fluency42), memory46), 
and global cognition44). A case–control study (n=446) 
reported that the Mini Mental State Examination 
(MMSE) score of CAD cases was lower than that of 
controls, but this was not statistically significant45). 
Furthermore, a prospective study (n=616) found that 
CAD patients had worse cognitive scores than had 
that increased CAC volume was associated with mod-
estly increased risk of dementia after 6 years of follow-
up18), but this result did not reach statistical signifi-
cance (HR 1.05 per Ln(calcium volume＋1.0 mm3), 
95%CI 0.80–1.36). On the other hand, in the Multi–
Ethnic Study of Atherosclerosis (MESA) study, which 
includes a population with broader age range and dif-
ferent races/ethnicities (n=6,293), there was a statisti-
cally significant increased risk of dementia after a 
median of 12.2 years (HR 1.18 per log2 (CAC score 
＋1), 95%CI 1.03–1.36)19). Because these two studies 
used different units to measure CAC, it was not possi-
ble to perform meta-analysis. A smaller study that 
mostly included women of ≥ 80 years (n=311) 
reported that white elderly women with CAC score ＞
400 had around three times higher risk of dementia 
after 10＋ years, compared with those with CAC score 
of 0 40). An even smaller study in type 1 diabetes 
Fig.1. Flowchart of literature search and selection
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Association with Cognitive Impairment or Dementia
Ten cross-sectional studies (n=200–616,245) 
reported on the association between CAD and clini-
cally diagnosed MCI (n=6) or dementia (n=4)25-28, 53-58). 
Five studies reported that CAD was significantly asso-
ciated with MCI/dementia, with ORs varying from 
1.60 to 6.76 25-28, 57). Four studies with MCI as out-
come did not find an association or reported a ten-
dency to an inverse association54-56, 58). The largest 
study found an OR of ischemic heart disease for 
dementia of 1.9 (95%CI 1.5–2.4)27). Meta-analysis 
was possible for eight studies25-28, 54, 56-58). Pooled OR 
of CAD for MCI/dementia was 1.66 (95%CI 1.17–
2.37), with significant heterogeneity between studies 
(I2=90.5%, p＜0.001) (Fig.2A). One study investi-
gated coronary atherosclerosis confirmed by autopsy 
and found that an increased burden of intracranial 
atherosclerosis, but not coronary atherosclerosis, was 
associated with dementia53).
Five case–control studies (n=410–23,912) evalu-
ated the association between CAD and MCI/demen-
tia10, 29-31, 59). The largest studies found slight but sig-
nificant positive associations, of which one focused on 
MCI (OR 1.17, 95%CI 1.04–1.32)31) and the other 
on dementia (OR 1.07, 95%CI 1.04–1.14)29). The 
controls at 1- and 5-year follow-up47), and a study 
with longer follow-up (7 years, n=380) found that 
CAD was associated with worse information process-
ing speed41). However, in a larger population-based 
cohort study in Norway (n=5,033), no association 
was found between CAD and cognitive test scores (12 
word memory test, digit-symbol coding test, and tap-
ping test)43).
Association with Cognitive Decline
Five longitudinal studies reported the relation-
ship between clinical CAD and change in cognitive 
function over time48-52). A relatively small study (n=  
231) found that the decline of global cognitive func-
tion over 2 years in patients with a history of CAD 
and normal heart function was not worse than that in 
patients without CAD48). In contrast to this, a larger 
study in 889 elderly (70–90 years) found that CAD 
was associated with greater decline in memory over 2 
years49). Similarly, a study in elderly men (n=353) 
found that CAD increased cognitive decline over 3 
years (OR 1.7, 95%CI 0.8–3.5)51). In addition, two 
other studies in 118 and 135 AD patients showed that 
CAD accelerated decline on both Clinical Dementia 
Rating scale and MMSE scores over ≥ 1–3 years50, 52). 
Fig.2. Forest plot of the association between clinical coronary artery disease and mild cognitive impairment or dementia in cross-
sectional studies. (A); in case–control studies (B); in cohort studies (C); and in all studies reporting odds ratio (D). 
OR, odds ratio; HR, hazard ratio
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erogeneous methodology and inconsistent findings. 
Two population-based studies investigated the associa-
tion between CAC and risk of dementia, both finding 
a tendency toward higher risk of dementia as CAC 
severity increased. Overall, cross-sectional, case–con-
trol, and longitudinal studies showed that clinical 
CAD was significantly associated with MCI/dementia, 
but high heterogeneity mainly caused by cross-sec-
tional studies. In clinical CAD, risk of MCI and 
dementia was increased by 50%. Compared with two 
prior systematic review articles on the association 
between CAD and cognitive function64, 65), our study 
has strengths that include the evaluation of subclinical 
CAD as assessed by CAC score in relation to dementia 
and restriction of clinical CAD studies to pre-cardiac 
intervention results.
Coronary Artery Calcium Score and Cognitive 
Function
The CAC score, a commonly used non-invasive 
imaging biomarker for subclinical CAD, is a robust 
predictor of cardiovascular events66). To our knowl-
edge, this is the first systematic review to assess the 
predictive value of CAC for cognitive outcomes. Two 
population-based longitudinal studies, MESA and 
Rotterdam study, found a tendency toward higher risk 
of dementia as CAC severity increased18, 19). As they 
used a different CAC scoring method, meta-analysis 
could not be performed. Conversely, some studies 
showed that intracranial artery atherosclerosis, but not 
coronary atherosclerosis, was associated with MCI and 
dementia53, 67). It is not irrational to presume that cor-
onary atherosclerosis and intracranial artery athero-
sclerosis are likely to be concomitant. Another possible 
explanation is that both coronary atherosclerosis and 
dementia are age-related diseases sharing risk factors 
such as smoking, hypercholesterolemia, hypertension, 
and diabetes6). Although we tried to stratify the stud-
ies that used adjustment for risk factors, this was not 
feasible because considerable heterogeneity existed in 
the number and type of confounders that were 
included in the models across studies. However, after 
adjusting for covariates that may affect the effect esti-
mates, CAC was still significantly associated with risk 
of dementia in the MESA study. Also, in clinical CAD 
studies with full adjustment for major cardiovascular 
risk factors, associations remained significant. These 
findings suggest a relationship between (sub)clinical 
CAD and dementia, beyond cardiovascular risk fac-
tors. Alternatively, the association between CAC and 
dementia may be explained by the potential mediating 
effect of cerebrovascular disease (e.g., stroke), since an 
association has been found between severity of CAC 
and risk of stroke68). However, in MESA, after exclud-
three smaller studies found no significant association 
between CAD with dementia10), AD59), or vascular 
dementia30). Four studies could be included in the 
meta-analysis with a resulting pooled OR of 1.08 
(95%CI 1.04–1.13) and no significant heterogeneity 
I2=0.0%, p=0.57 (Fig.2B).
Nine prospective studies (n=376-49,955) with fol-
low-up from 2.4 to 25.5 years addressed the association 
between CAD and risk of MCI/dementia11-13, 32, 33, 60-63. 
Five studies showed that clinical CAD significantly 
increased the risk of dementia, with HRs of 2.1–
2.9 13, 32, 33, 60, 63). In the Rotterdam study, unrecognized 
MI determined by electrocardiography was not related 
to dementia overall; however, there was a positive asso-
ciation in men (HR 2.23, 95%CI 1.24–4.01)62). 
Another two studies found that patients with MI, 
mostly based on self-report, tended to have a higher 
risk of dementia (HR 1.1–1.3)12, 61). One study inves-
tigated the association of midlife CAD (diagnosed at 
or before baseline examination) and late-life CAD 
(diagnosed at or before first re-examination) with 
dementia and found that midlife CAD was not associ-
ated with dementia, whereas participants with late-life 
CAD tended to have a higher risk of dementia (HR 
1.66, 95%CI 0.81–3.16)11). Meta-analysis was con-
ducted in studies that reported HRs11-13, 61-63) and 
studies that reported ORs32, 33, 60) separately. Pooled 
HR and pooled OR of CAD for MCI/dementia were 
1.51 (95%CI 1.24–1.85, I2=14.1%, p=0.32) and 2.65 
(95%CI 1.62–4.33, I2=0.0%, p=0.96), respectively 
(Fig.2C). The funnel plot was symmetric (Supple-
mentary Fig.1C) for the pooled HR, whereas formal 
statistical testing was not performed because of insuf-
ficient number of studies. Sensitivity analysis did not 
detect any study that was of particular influence on 
the pooled HR.
Finally, an overall effect size of the association of 
CAD with MCI/dementia was calculated by including 
the data from all cross-sectional, case–control, and 
cohort studies (n=15). Pooled OR of CAD for MCI/
dementia was 1.32 (95%CI 1.17–1.48), with signifi-
cant heterogeneity between studies (I2=87.0%, p＜ 
0.001) (Fig.2D). The funnel plot (Supplementary 
Fig.1E) displayed asymmetry, with Egger’s test p value 
＜0.001. Sensitivity analysis did not detect any study 
that was of particular influence on the pooled OR.
Discussion
This systematic review, including 46 studies, 
evaluated the current evidence of the association 
between (sub)clinical CAD and cognitive function. 
Prior studies about associations of (sub)clinical CAD 
with cognitive function and cognitive decline had het-
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symmetric, indicating unlikely presence of bias. Nev-
ertheless, pooling cohort and case–control studies 
together with cross-sectional studies indicated poten-
tial presence of bias. It may be due to high heteroge-
neity among cross-sectional studies, or it is likely that 
cross-sectional studies with a negative result were not 
published. This may lead to potential overestimation 
of the results. To deal with this issue, more longitudi-
nal cohort studies are needed to validate the suggested 
association. As longitudinal cohort studies are assumed 
to have a higher level of evidence, we also pooled the 
results from these high-quality studies only. For these 
studies (n=6), we found that CAD is significantly 
associated with risk of dementia (pooled HR 1.51, 
95%CI 1.24–1.85), and this time with minor inter-
study heterogeneity (I2=14.1%, p=0.32).
Deckers et al. and Wolters et al.64, 65) also con-
ducted systematic reviews to evaluate the association 
between CAD and dementia, and both studies found 
a significant association but with different estimated 
pooled effects. Deckers et al. performed a meta-analy-
sis in seven longitudinal cohort studies resulting in an 
OR of 1.55 (95%CI 1.20–2.00), whereas Wolter et al. 
included nine population-based cohorts resulting in a 
pooled relative risk of 1.26 (95%CI 1.06–1.49)64, 65). 
In our systematic review, we also found a significant 
association between the two diseases, with increased 
risk estimates very similar to the prior results. The dif-
ference in OR between the study of Deckers et al. and 
our study (1.55 vs 1.32) may be explained by the dif-
ference in selection criteria and consequent difference 
in studies included for the final analysis. The prior 
systematic reviews did not exclude studies that com-
prise patients with invasive coronary artery revascular-
ization such as coronary artery bypass grafting before 
assessment of cognitive function. Invasive coronary 
interventions themselves may influence the association 
between CAD and cognitive function, as, for example, 
hypoperfusion during bypass surgery can impair the 
washout of microemboli, with potential subsequent 
brain ischemia and infarction, and increased long-
term risk of dementia69). Although there is no study 
that directly compared invasive coronary interventions 
with medical management regarding cognitive out-
comes, many have reported that cardiac catheteriza-
tion increases the risk of silent cerebral infarction, 
which is related to cognitive decline22, 70). Further-
more, other cardiovascular diseases including stroke, 
atrial fibrillation, and heart failure can contribute to 
cognitive decline and dementia8, 9, 71). We accounted 
for the effect of invasive interventions and the latter 
cardiovascular diseases on the association between 
clinical CAD and cognitive function in the selection 
of studies so that the magnitude of association would 
ing interim stroke, associations between CAC score 
and risk of dementia remained statistically significant 
(HR 1.18, 95%CI 1.03–1.36)19), although associa-
tions between CAC volume and risk of dementia 
became statistically nonsignificant in the Rotterdam 
study (HR 1.05, 95%CI 0.80–1.36)18). Future studies 
need to clarify whether CAC merely reflects general-
ized atherosclerosis, confounded by shared risk factors, 
or whether coronary atherosclerosis is more directly 
related to MCI/dementia, and to which type of 
dementia. Even so, since the CAC score is increasingly 
used in cardiovascular risk stratification in cardiac 
asymptomatic individuals, our results can raise aware-
ness of the elevated risk of dementia in individuals 
with increased CAC at a very early stage and thus 
allow for timely prevention of cognitive decline.
Clinical Coronary Artery Disease and Cognitive 
Function
By pooling results of all study types (n=15), we 
found a significant association between CAD and 
MCI/dementia, with a pooled OR of 1.32 (95%CI 
1.17–1.48); however, substantial heterogeneity exists 
between studies (I2=87.0%, p＜0.001). This hetero-
geneity likely has multiple causes. Many different 
study designs and patient samples were included. Also, 
differences in the definition and assessment of CAD 
may have contributed. For example, the definition of 
clinical CAD comprised MI or AP or both. Compared 
with the use of medical records and tests such as elec-
trocardiography, a self-report strategy used by some 
studies for the diagnosis of CAD is less objective and 
may increase information bias. In addition, there was 
diversity in assessment of cognitive function and there 
may have been differences in percentage of dementia 
subtypes. Most studies used the Diagnostic and Statis-
tical Manual of Mental Disorders for diagnosis of 
dementia without specifying subtypes; only a few 
studies clearly differentiated dementia subtypes25, 30, 61, 63). 
Also, differences in duration of the follow-up period 
may play a role. For example, in the study by Hayden 
et al., there was no significant association between 
clinical CAD and dementia after a relatively short fol-
low-up period (about 3 years), whereas associations 
may only become manifest after a longer time61). 
Finally, differences in study populations may have 
contributed to heterogeneity. The majority of the 
studies in the meta-analysis was population based. The 
study of Haring et al. is an exception, as it consists of 
a cohort of postmenopausal women13). 
With respect to reporting bias, the number of 
studies per study design was insufficient to be able to 
perform a formal statistical test; however, the funnel 
plots of cohort and case–control studies were visually 
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an association between (sub)clinical CAD and cogni-
tive function. Limited evidence suggests the CAC 
score is associated with risk of dementia. In clinical 
CAD, risk of MCI and dementia is increased by 50%, 
as supported by stronger evidence. These findings call 
for further investigation of whether and how coronary 
atherosclerosis is involved in the etiology and patho-
genesis of cognitive decline and dementia and whether 
the relationship differs by type of dementia.
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Supplementary Table 1. Literature search strategy
Search Strings 
Pubmed
(“Myocardial Ischemia”[Mesh] OR “Atherosclerosis”[Mesh:Noexp] OR coronary atherosclerosis[tiab] OR coronary artery disease [tiab] OR 
coronary heart disease [tiab] OR coronary calcium[tiab] OR coronary calcification[tiab] OR coronary calcific[tiab] OR coronary 
calcified[tiab] ) 
AND
(“Dementia”[Mesh] OR “Cognitive Dysfunction”[Mesh] OR dementia [tiab] OR Alzheimer*[tiab] OR cognitive impairment[tiab] OR 
cognitive decline[tiab] OR cognitive function[tiab] OR cognitive disorder[tiab] OR cognitive performance [tiab] OR cognitive 
dysfunction[tiab]) 
NOT (“Animals”[Mesh] NOT “Humans”[Mesh])
EmBase
(‘coronary artery disease’/exp OR ‘coronary artery calcium score’/exp OR ‘coronary atherosclerosis’:ab,ti OR ‘coronary artery disease’:ab,ti 
OR ‘coronary heart disease’:ab,ti OR ‘coronary calcium’:ab,ti OR ‘coronary calcification’:ab,ti OR ‘coronary calcific’:ab,ti OR ‘coronary 
calcified’:ab,ti)
AND
(‘mild cognitive impairment’/exp OR ‘dementia’/exp OR ‘dementia’:ab,ti OR ‘alzheimer disease’:ab,ti OR ‘mild cognitive impairment’:ab,ti 
OR ‘cognitive decline’:ab,ti OR ‘cognitive function’:ab,ti OR ‘cognitive disorder’:ab,ti OR ‘cognitive performance’:ab,ti OR ‘cognitive 
dysfunction’:ab,ti)
NOT (‘animal’/exp NOT ‘human’/exp)
Web of Science
#1 TS= (coronary artery disease) OR TS= (Coronary atherosclerosis) OR TS= (coronary artery calcium score) OR TS= (coronary calcium) 
OR TS= (coronary calcified) OR TS= (coronary calcific) OR TS= (coronary calcification) OR TS= (coronary heart disease)
#2 TS= (dementia) OR TS= (mild cognitive impairment) OR TS= (alzheimer) OR TS= (cognitive function) OR TS= (cognitive 
dysfunction) OR TS= (cognitive disorder) OR TS= (cognitive performance) OR TS= (cognitive decline)
#3 #1 AND #2
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Supplementary Table 2. Characteristics of included studies on the association between coronary artery calcium and cognitive function
Study, year Study setting Study population No. of 
Participants
Age (Mean, SD), 
years
Female, % Follow-up 
(Mean, SD), 
years
Topic 1: Association with cognitive function 
Cross-sectional
Reis, 2013 35) Cross-sectional analysis of coronary 
artery risk development in young 
adults (CARDIA) study 
Multi-center, community 
based including black and 
white 
2,510 Range 43-55 years 54.9 NA
Vidal, 2010 16) Cross-sectional analysis of the age, 
gene, environment susceptibility 
(AGES) - Reykjavik study
Residents in Reykjavik, 
Iceland
4,250 Range 74.5-78.0 75.0 NA
Suemoto, 
2017 34)
Cross-sectional analysis of Brazilian 
Longitudinal Study of Adult Health 
(ELSD-Brasil) study
Residents in São Paulo 
Center, Brazil




Cross-sectional analysis of Diabetes 
Heart Study (DHS) –Mind























Cross-sectional analysis of Dallas 
heart study (DHS)
African American, white, 
Hispanic
1,154 50.9±10.4 58.0 6
Topic 2: Association with changes of cognitive function over time (longitudinal)
Jacobson, 
2011 38)
Prospective cohort of Diabetes control 
and complications trial (DCCT)/ 
Epidemiology of diabetes 
interventions and complications 
(EDIC) study
Type 1 diabetes patients 1,144 45.7±6.8 47.0 18.5 
Topic 3: Association with MCI/dementia 
Longitudinal (risk of MCI/dementia)









Prospective cohort of Multi-Ethnic 
Study of Atherosclerosis (MESA) 
12.2% Chinese, 26.1% 







68.4±5.9 52.5 12.2 
(Median)
Kuller, 2016 40) Prospective cohort of Cardiovascular 
Health Study
Predominantly 80＋ years 
(white, African-American, 
others)
311 ≥ 80 65.0 10＋
Guo, 2019 39) Pittsburgh epidemiology of diabetes 
complications (EDC) study
Diagnosed with childhood-
onset type 1 diabetes
148 37.2±7.0 51.0 14.0±3.5
SD, Standard Deviation; T2DM, Type 2 Diabetes Mellitus; NA, Not applicable.
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Supplementary Table 3. Characteristics of included studies on the association between coronary artery disease and cognitive function
Study, year Study setting Study population No. of 
Participants











Cross-sectional analysis of Berlin 
aging study (BASE) in Germany
Locally representative 
sample predominantly above 
70 years old 
516 84.9 50.0 NA
Elwood, 
2002 44)
Cross-sectional analysis of the 
Caerphilly cohort in South Wales
Representative sample of 
men
Around 1,700 Range 55-69 0 NA
Lyall, 
2017 46)
Cross-sectional analysis of baseline 
UK Biobank cohort












Longitudinal cohort of Oxford 
Vascular Study in UK















Hoorn Study, Netherland Population based 380 Range 50-75 50.0 Cognitive 
function 
assessed 7 










years after the 
assessment of 
CAD
Topic 2: Association with changes of cognitive function over time (longitudinal)
Lipnicki, 
2013 49)
Longitudinal cohort of Sydney 
Memory and Ageing Study (MAS) 
in Australia
Community based 889 78.6±4.8 54.1 2
Kalmijn, 
1996 51)
Longitudinal cohort of the Zutphen 
Elderly Study in Netherlands
Men living in Zutphen 353 74.6±4.2 0 3
Almeida, 
2012 48)
Prospective case control, Heart Mind 
study in the western Australia
Community volunteers 231 (controls 













Longitudinal cohort of Cache 
County Study on Memory, Health, 
and Aging (CCSMHA), Utah in the 
United States
Local residents with 
Alzheimer disease
135 84.2±6.5 65.9 ≥ 1
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(Cont Supplementary Table 3)
Study, year Study setting Study population No. of 
Participants
Age (Mean, SD), 
years





Longitudinal cohort of Ageing, 
cognition, and dementia in primary 
care patients (AgeCoDe) in Germany
Patients with AD from 
primary health care
118 85.6±3.3 74.6 3 




Cross-sectional study in North 
China
Community based 3,136 Range 60-80＋ 59.3 NA
Roberts, 
2010 54)
Cross-sectional in Olmsted county, 
the United States
Residents 1,969 80.4 49.1 NA
Zou, 
2014 56)
Cross-sectional study in China Hospital and community 
based
597 Range 60 - 95 56.6 NA
Hai, 
2012 26)
Cross-sectional study in China Residents in Southwest 
China
202 82.5±2.1 25.7 NA
Kuroki, 
2018 57)
PROST (Project in Sado for Total 
Health) study in Japan
Outpatients 565 Range 62-79 48.7 NA
Stephan, 
2017 58)
Cognitive Function and Ageing 
Study (CFAS) in UK





Cross-sectional study in Scotland Population based 616,245 
(1,061 cases)
Range 40-64 49.5 NA
Ross, 
1999 25)
Cross-sectional analysis of a 
Honolulu Heart Program, 
Honolulu-Asia aging study in 
Hawai, the United States




no stroke no 
dementia 
3,335)
Range 71-93 0 NA
Deng, 
2018 28)
Cross-sectional study in Chongqing, 
China
Residents 1,781 ≥ 60 60.5 NA
Dolan, 
2010 53)
Cross-sectional analysis of Baltimore 
Longitudinal Study of Aging (BLSA) 
Autopsy Program in the United 
States






Retrospective case control of the 
Disease Analyzer database (IMS 
Health) in Germany





of MCI; 3,604 
controls 
without MCI)
75.2±9.1 45.3 3 years of 
continuous 
follow-up 
prior to the 




Retrospective case control in 
Rochester, the United States










Retrospective case control study in 
the University of Torino, Italy 
Consecutive patients and 
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(Cont Supplementary Table 3)
Study, year Study setting Study population No. of 
Participants
Age (Mean, SD), 
years





Retrospective case control of the 
Disease Analyzer database (IMS 
Health) in Germany

















Retrospective case control at Mayo 
Clinic in Olmsted County, USA
Patients living within 
Olmsted County received 
care at the Mayo Clinic






Longitudinal (risk of MCI/dementia)
Newman, 
2005 12)
Longitudinal cohort of 
Cardiovascular Health Study (CHS) 
in US
Community based 2,539 Range 65-97 60.0 5.4
Rusanen, 
2014 11)
Longitudinal cohort of 
Cardiovascular Risk factors, aging 
and dementia (CAIDE) study, 
Finland









Cache County Study of Memory 
Health and Aging (CCSMHA), USA
Residents of Cache Country, 
Utah, USA
3,264 74.0±6.4 58.2 3.2 
Haring, 
2013 13)
Longitudinal cohort of Women’s 
Health Initiative Memory Study 
(WHIMS) in the United States
Postmenopausal women 6,445 Range 65-79 100.0 8.4 median
Ikram, 
2008 62)
Longitudinal cohort of Rotterdam 
Study in Netherland



















A prevalence and incidence study of 
dementia in Cambridge city
Participants were from 
selected group general 
practices
376 ≥ 75 63.6 2.4
Kivipelto, 
2002 33)
Prospective FINMONICA study in 
Finland
Population based 1,287 Range 65-79 61.8 21.0±4.9
Chen, 
2011 32)
Prospective Anhui cohort study in 
China
Residents 1,307 ≥ 65 NR 3.9 median
Lin, 
2017 63)
Taiwan’s National Health Insurance 
Research Database





Range 29-51 61.2 ~7
CAD, Coronary Artery Disease; SD, Standard Deviation; ACS, Acute Coronary Syndrome; TIA, Transient Ischemic Attack; NA, Not Applicable; 
NR: not reported; CHD, Coronary Heart Disease; CHF, Chronic Heart Failure; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; MI, 
Myocardial Infarction.
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Supplementary Table 4.  Exposure and outcomes of included studies on the association between coronary artery calcium and cog-
nitive function
Study, year CT type Type of Cal-
cium score
Data type of 
input variable
Outcomes Adjustments for confound-
ers
Main results
Topic 1: Association with cognitive function
Cross-sectional






assessed with the DSST,  
Stroop Test, and RAVLT.
Age, sex, race, educational 
level, study center, BMI, 
smoking status, alcohol use, 
dyslipidemia, hypertension, 
and diabetes
Higher CAC  was signifi-
cantly associated with lower 
DSST score.






Prevalence of dementia and 
cognitive scores of separate 
cognitive domains
Age, education level pres-
ence of depressive symp-
toms and cardiovascular 
risk factors including ever 
smoker, prevalent coronary 
heart disease, current 
hypertension and diabetes, 
and midlife systolic pressure 
and total cholesterol
Increasing quartile of CAC 
associated with lower cog-
nitive scores of speed of 
processing, executive func-







100: absent or 
mild atheroscle-




Cognitive function was 
assessed by using DWRT, 
CFT, TMT by trained 
examiners
Age, sex, race, marital sta-




hol use, physical activity, 
BMI, depression and thy-
roid function status
Participants with CAC ≥ 
100 had worse cognitive 
performance in global cog-
nition, DWRT TMT 










tested with a battery of tests 
including DSST, RAVLT 
and Semantic Fluency Task.
Age sex and education Higher burden of coronary 
calcification was signifi-
cantly associated with 
worse cognitive perfor-
mance on DSST, RAVLT, 
and semantic fluency task 
after a mean of 6.7 years, 











MoCA Scores NA Mean of MoCA total score 
(SD) after about 6 years 
was 23.69 (3.87) for CAC 
≤ 10:, and 22.35 (4.40) for 
CAC ＞10, p-value 0.038.







Deterioration of cognitive 
scores on 8 cognitive 
domains
Sex, baseline age, baseline 
education level, painful 
neuropathy reported at fol-
low-up, visual acuity, length 
of follow-up, the number of 
interval cognitive tests taken
No evidence supporting 
the association between 
presence of coronary calci-
fication and rapid decline 
of cognitive scores in 
T1DM patients.
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(Cont Supplementary Table 4)
Study, year CT type Type of Cal-
cium score
Data type of 
input variable
Outcomes Adjustments for confound-
ers
Main results
Topic 3 : Association with MCI/dementia 
Longitudinal (risk of MCI/dementia)
Bos, 2015 17) MDCT Volume score Ln(calcification 
＋1.0 mm3)
Incidence of dementia was 
diagnosed according to 
DSM-III-R 
Age, sex and education level CAC score was not signifi-
cantly associated with risk 
of dementia: HR 1.05 
(95% CI 0.80, 1.36), of 
AD: HR 1.09 (95%CI 










Incidence of dementia was 
diagnosed based on ICD10 
codes
Age, sex, race, education 
level, having health insur-
ance, physical activity, 
smoking, obesity, hyperten-
sion, medications for hyper-
tension or dyslipidemia, 
systolic blood pressure, 
non-HDL cholesterol, dia-
betes, APOE epsilon-4 gen-
otype
log2 (CAC score ＋1) was 
significantly associated 
with risk of dementia (HR 
1.18; 95% CI 1.03, 1.36) 
after multivariable adjust-







 (0, 1-10, 
11-100, 101-
400, ＞400)
Incidence of dementia basis 
of standard criteria
NA White women with a CAC 
score ＞400 had around 3 
times higher risk of demen-
tia than those with CAC 
score=0.






defined as having two or 
more of cognitive test scores 
≥ 1.5 SD worse than norms 
Education, sex, age, diabe-
tes duration, APOE epsi-
lon-4, ever smoking, BMI, 
HbA1c, cholesterols (HDL 
and non-HDL), triglycer-
ides, urinary albumin excre-
tion rate, hypertension, 
proliferative retinopathy, 
distal symmetric polyneu-
ropathy, and statin use were 
offered for model selection.
Compared to CAC  
score=0, OR (95%CI) of 
MCI for CAC score 1-100, 
101−300 and ＞300 were 
1.4 (0.6, 3.6), 2.3 (0.6, 
9.7), and 7.9 (1.6, 38.5), 
respectively.
CAC, Coronary Artery Calcium ; CT, Computed Tomography; MDCT, Multi-detector Computed Tomography; EBT, Electron Beam Tomogra-
phy; SD, Standard Deviation; BMI, Body Mass Index; LDL, Low-density Lipoprotein; HDL, High-density Lipoprotein; DSST, Digit Symbol Sub-
stitution Task; RAVLT, Rey Auditory-verbal Learning Task; MoCA, Montreal Cognitive Assessment; DWRT, Delayed Word Recall Test; CFT, Cat-
egory Fluency Test; TMT, Trail Making Test; T2DM, Type 2 Diabetes Mellitus; HR, Hazard Ratio; CI, Confidence Interval; ICD10, International 
Statistical Classification of Diseases and Related Health Problems 10th version; DSM-III-R, Diagnostic and Statistical Manual of Mental Disorders 
Version III Revised; AD: Alzheimer’s Disease; NA, not available; APOE, apolipoprotein E
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Supplementary Table 5.  Exposure and outcomes of included studies on the association between coronary artery disease and cogni-
tive function
Study, year Ascertainment of exposure Outcomes Adjustments for confounders Main results




In order to ascertain MI and 
CHD diagnoses, medical 
history, physical examination, 
resting ECG results, interview 
with family doctor were 
considered
Cognitive performance 
including perceptual speed, 
episodic memory, fluency 
and knowledge was assessed 
using cognitive test battery 
separately
Age, sex, social-economic  
status
Prevalent of CHD associated 




Medical history of IHD 
including previous MI, ECG 
ischemia, angina recorded via 
interviews as well as ECG 
testing
Tests of cognitive function 
including AH4, CAMCOG, 
MMSE and the Choice 
Reaction Time were 
performed
Age, education level, mood at 
the time of testing
Compared with men without 
disease, decrements in men 
with IHD was 16% SD for the 
AH4, 13% SD for the MMSE, 
14% SD for the CAMCOG 
and 17% SD for the CRT.
Lyall, 2017 46) CAD defined as history of 
physician-diagnosed angina and/
or MI.
Cognitive abilities were 
tested by three tests including 
verbal-numerical reasoning, 
visual memory test and 
reaction time test.
Age, sex, ethnicity, depression, 
education, Townsend 
deprivation score, smoking 
status, alcohol intake, 
medication use and BMI
Presence of CAD associated 
with poorer cognitive scores, 
for reasoning (effect size 
-0.107, 95%CI -0.135, 
-0.079), log reaction time 
(effect size 1.005, 95%CI 
1.004, 1.007), log memory 
error scores (effect size 1.017, 
95%CI 1.011, 1.023).
Case control
Ahto, 1999 45) MI ascertained by checking 
medical records or ECG results. 
AP defined as chest pain on 
effort fulfilling the Rose 
questionnaire’s criteria.
Cognitive impairment 
defined as total MMSE 
scores under 23 tested by 2 
trained nurses.
NA MMSE score (mean±SD) 
among Men: CAD 26.5±4.9, 
Controls 27.0±3.6 (p-value 
0.70); among Women: CAD 





IHD defined as Minnesota 
codes on ECG or self-reported 
history of MI
Neuropsychological test 
battery was used for cognitive 
assessment
Age and sex Presence of IHD significantly 




Definition of CHD was history 
of MI and/ or prevalent AP
Cognitive performance 
assessed by the twelve word 
memory test, digit-symbol 
coding test and tapping test.
Age, education, physical 
activity, smoking systolic blood 
pressure, total cholesterol, 
HDL-cholesterol, BMI, 
diabetes, depression
No evidence supporting CHD 




ACS defined as ST elevation and 
non-ST elevation MI, or 
unstable angina, according to 
currently accepted criteria
Cognitive function assessed 
using MMSE, TICSm, and 
MoCA by trained research 
nurses.
NA ACS patients had worse 
cognitive function than those 
with TIA 
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(Cont Supplementary Table 5)
Study, year Ascertainment of exposure Outcomes Adjustments for confounders Main results
Topic 2: Association with changes of cognitive function over time (longitudinal)
Lipnicki, 
2013 49)
CAD defined as previous 
diagnosis of MI or angina.
Cognitive performance 
assessed by a battery of 
neuropsychological tests 




History of MI and AP obtained 
from a standardized 
questionnaire
Cognitive decline defined as 
a decrease in MMSE of above 
1 SD from 1990 to 1993
Age, education and baseline 
MMSE score
History of CAD increased the 
risk of cognitive decline with 
OR 1.7 (95%CI 0.8, 3.5).
Almeida, 
2012 48)
Clinical and biochemical 
evidence of past MI with normal 
left ventricular function and no 
clinical symptoms of congestive 
heart failure
CAMCOG scores Age, sex and CAMCOG scores 
at baseline
No difference between CAD 
and control groups on changes 
of CAMCOG.
Mielke, 2007 52) Information on previous MI 
obtained via proxy and self-
report
Decline as reflected by scores 
of MMSE and CDR
Age, sex, education, dementia 
duration, APOE epsilon-4, 
depression, baseline MMSE 
score
MI and AP predicted cognitive 




Diagnosis of CHD or MI 
reported by GPs
Decline of cognitive function 
in patients with AD assessed 
by MMSE and the CDR
Age, sex, education, and time 
since dementia diagnosis
Presence of CHD related to 
rapid decline of cognition in 
patients with AD.
Topic 3: Association with MCI or dementia
Cross-sectional
Wang, 2015 55) CHD checked through medical 
history
Diagnostic criteria of MCI 
was according to the proposal 
of Petersen et al.
Not clarified CHD was not associated with 
MCI (effect size not reported).
Roberts, 
2010 54)
Ascertainment and criteria 
described in reference, in brief 
the assessment was based on 
medical history, diagnostic test, 
and ICD codes. 
Prevalent MCI including 
amnestic and non-amnestic 
subtypes diagnosed according 
to published criteria
Age, sex, years of education, 
diabetes, hypertension, stroke, 
BMI, depression, dyslipidemia, 
APOE genotype
OR of MI for MCI was 0.91 
(95%CI 0.55, 1.49).
Zou, 2014 56) History of coronary heart disease 
including silent MI, AP, MI, or 
ischemic cardiomyopathy, 
assessed by ECG and color 
doppler ultrasound 
MCI diagnosed according to 
patients complains and 
MMSE and CDR scores.
Age, gender and education OR of CHD for MCI, OR 
0.988 (95%CI 0.981, 0.996).
Hai, 2012 26) History of CHD ascertained by 
interview
MCI diagnosed following the 
criteria proposed by Petersen 
et al. 
Not clarified OR of CHD for MCI 6.76 
(95%CI 2.74, 16.67).
Kuroki, 2018 57) Medical history of IHD 
obtained from clinical records
MMSE score ＜24 
considered to indicate MCI.
Age, sex, smoking and drinking 
habit, number of teeth
OR of IHD for MCI 2.73 
(95% CI 1.32, 5.67)
Stephan, 
2017 58)
CHD composite variable 
incorporating the presence of 
self-reported heart attack (single 
question asking about the 
presence or absence of the 
condition) or angina based on 
the Rose Diagnostic Scale.
MMSE score ＜24 
considered to reflect MCI.
Age, sex, years of education, 
disease comorbidity
OR of CHD for MCI 1.02 
(95%CI 0.71-1.40).
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Study, year Ascertainment of exposure Outcomes Adjustments for confounders Main results
Heath, 2014 27) Information of IHD extracted 
using electronic medical records
Diagnosis of dementia 
fulfilled DSM-IV 
Age, sex, neurodegenerative 
disorder, learning disability, 
socioeconomic status
OR of IHD for dementia 1.9 
(95%CI 1.5, 2.4)
Ross, 1999 25) Prevalent CHD defined as MI 
or AP without describing 
ascertainment method
Vascular dementia diagnosed 
based on the criteria 
proposed by California 
Alzheimer Disease Diagnostic 
and Treatment Centers
Age  OR of CHD for vascular 
dementia 2.60 (95%CI 1.59, 
4.25).
Deng, 2018 28) CHD ascertained by 
questionnaire
Dementia diagnosis based on 
the criteria of the Diagnostic 
and Statistical Manual of 
Mental Disorders
Living area, age, marital status, 
smoking, exercise, social 
activities, BMI, hypertension, 
depression
OR of CHD for dementia 
1.596 (95%CI 1.017–2.506)
Dolan, 2010 53) Coronary atherosclerosis 
examined postmortem
Diagnosis of dementia based 
on DSM-III-R and the 
pathology assessed by 
autopsy
Age, sex No association between 
coronary atherosclerosis and 
dementia
Case control
Jacob, 2017 31) CHD diagnosed based on ICD 
codes I20-I25
MCI diagnosed based on 
ICD 10 codes by neurologists 
or psychiatrists
Disorders including, anxiety, 
depression, hyperlipidemia, 
obesity, hypertension, diabetes 
OR of CHD for MCI 1.17 
(95%CI 1.04, 1.32).








History of acute MI AD diagnosed according to 
DSM-III and the NINCDS-
ADRDA work group criteria
NA No significant difference 
between AD and controls 
regarding a history of acute MI
Booker, 2016 29) CHD diagnosed in primary care 
based on ICD codes I20-I25









History of angina and diagnosis 
of 
Clinically documented 
diagnosis of definite vascular 
dementia based upon the 
NINDS-AIRENcriteria
Not adjusted ORs of angina and previous 
MI for vascular dementia 1.22 
(95%CI 0.79, 1.88) and 1.11 
(95%CI 0.66, 1.87) 
respectively.
Longitudinal (risk of MCI/dementia)
Newman, 
2005 12)
Prevalent MI and AP assessed by 
self-report and confirmed by 
medical records, test results, 
medication use.
Incidence of dementia 
diagnosed based on clinical 
criteria
Age, race, education, income, 
APOE episilon-4, modified 
MMSE score
HR of MI for dementia 1.3 
(95%CI 1.0, 1.9) and HR of 
AP for incident of dementia 
1.3 (95%CI 1.0, 1.7) 
Rusanen, 2014 11)CAD based on ICD codes, 
ascertained by self-reported 
history of MI or AP 
Incidence of dementia 
diagnosed according to the 
DSM-IV 
Sex, education, systolic blood 
pressure, cholesterol, BMI, 
APOE, smoking, physical 
activity, diabetes or impaired 
glucose tolerance
HR of CAD diagnosed midlife 
(at or before baseline) and late-
life (at or before first 
reexamination) for dementia 
0.80 (95%CI 0.38, 1.67) and 
1.66 (95%CI 0.87, 3.16), 
respectively 
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Study, year Ascertainment of exposure Outcomes Adjustments for confounders Main results
Hayden, 2006 61) History of MI obtained by 
interview
Dementia diagnosed 
according to DSM-III-R, the 
NINCDS-ADRDA  criteria 
was used for AD diagnoses. 
Vascular dementia was 
identified with the NINDS-
AIREN criteria. 
Age, sex, education, APOE 
episilon-4, hypertension, high 
cholesterol, diabetes, obesity
HR of MI for dementia 1.13, 
(95%CI 0.59, 2.03), for AD 
1.11, (95%CI 0.49, 2.26) and 
for vascular dementia 1.06, 
(95%CI 0.34, 2.93)
Haring, 2013 13) MI defined as reported history 
of clinical MI, or ECG results 
with evolving Q-wave
Measures for incidence of 
MCI or probable dementia 
based on DSM-IV
Age, education, race, smoking, 
alcohol intake, physical activity 
diabetes, sleep hours, 
hypertension, BMI, 
depression, waist-hip ratio, 
hypercholesterolemia, aspirin 
use
HR of MI for dementia 2.18 
(95%CI 1.19, 3.99), for MCI 
2.56 (95%CI 1.64, 4.01) and 
for MCI or dementia 2.10 
(95%CI 1.40, 3.15)
Ikram, 2008 62) MI including unrecognized, 
Q-wave and recognized subtypes 
screened by interview and then 
confirmed by clinical data and 
ECG characteristics
Incident dementia 
ascertained following a 3-step 
protocol and diagnosed based 
on DSM-III-R
Age, sex, APOE episilon-4, 
systolic blood pressure, 
diastolic blood pressure, BMI, 
diabetes, atrial fibrillation, 
current smoking, intima media 
thickness, total cholesterol and 
HDL cholesterol
 HR of unrecognized MI for 
dementia 2.23, (95%CI 1.24, 
4.01) in men, in women 1.17, 
(95%CI 0.74, 1.83), and in 
total 1.35, (95%CI 0.95, 
1.92).
Brayne, 1998 60) History of heart attack 
ascertained from informants
Incidence of dementia 
ascertained based on the 
clinical criteria
Age, sex OR of history of MI for 




History of MI assessed with a 
self-administrated questionnaire
Dementia diagnosed 
according to the criteria of 
the DSM-IV
Age, APOE episilon-4, 
education level, sex, smoking, 
alcohol consumption
OR of MI for AD or vascular 
dementia 2.5 (95%CI 1.2, 5.4)
Chen, 2011 32) Doctor-diagnosed angina 
recorded
Dementia diagnosis based on 
DSM-III 
Age, sex, BMI, urban-rurality, 
socio-economic status, 
smoking, social network, 
psychosocial factors
OR of Angina for dementia 
2.58 (95%CI 1.01, 6.59).
Lin, 2017 63) ICD-9-CM used for diagnosis 
coding, further specified for 
CHD
Vascular dementia (ICD-
9-CM code 290.4x) 
diagnosed by a psychiatrist or 
a neurologist
Age, sex, comorbidities like 
hypertension, diabetes, 
dyslipidemia; urbanization 
level, monthly income level, 
depressive disorder
HR of CHD for vascular 
dementia in patients with and 
without depression 2.26 
(95%CI 1.07, 4.75)
CAD, Coronary Artery Disease; IHD, Ischemic Heart Disease; ECG, electrocardiogram; CHD, Coronary Heart Disease; MI, Myocardial Infarc-
tion; SD, Standard Deviation; CAMCOG, Cambridge Cognitive Examination of the Elderly Revised; MoCA, Montreal Cognitive Assessment; 
MMSE, Mini Mental State Examination; AP, Angina Pectoris; ACS, Acute Coronary Syndrome; BMI, Body Mass Index; HDL, High-density Lipo-
protein; TICSm, Telephone Interview for Cognitive Status-modified; TIA, Transient Ischemic Attack; OR, Odds Ratio; CI, Confidence Interval; 
CDR, Clinical Dementia Rating; MCI, Mild Cognitive Impairment; AD, Alzheimer’s Disease; GP, General Practitioner; DSM-III-R, Diagnostic 
and Statistical Manual of Mental Disorders Version III Revised; HR, Hazard Ratio; ICD, International Statistical Classification of Diseases and 
Related Health Problems NINCDS-ADRDA : National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
Disease and Related Disorders Association; NINDS-AIREN: National Institute of Neurological Disorders and Stroke and Association Internatio-
nale pour la Recherche et l’Enseignement en Neurosciences; NA, not available; APOE, apolipoprotein E 
Quality assessment
Advance Publication Journal of Atherosclerosis and Thrombosis 
Accepted for publication: November 18, 2019    Published online: February 15, 2020
Coronary Atherosclerosis and Cognition
23















The subjects in different out-
come groups are comparable, 








































































Star is rewarded for each item when the study presents the feature of quality. Each study can be rewarded a maximum of one star for each item 
except a maximum of two stars can be given to the items including ascertainment of the exposure (risk factor), comparability and assessment of the 
outcome. In brief, the quality criteria were defined as follows: representativeness of the sample: all subjects or random sampling; sample size: justi-
fied and satisfactory; non-respondents: response rate is satisfactory, characteristics between respondents and non-respondents were comparable ; 
ascertainment of exposure (risk factor): validated measurement tool=2 stars, non-validated measurement tool, but the tool is available or 
described=1 star; comparability: study controls for most important factor (defined as age and sex) (1 star) and control for any additional factor 
(defined as cardiovascular risk factors) (1 star); assessment of the outcome: was independent blind assessment or record linkage=2 stars, self-
report=1 star; statistical test: clearly described and appropriate, and the measurement of the association is presented including confidence intervals 
and the p value.
Supplementary Table 7. Quality assessment of case-control studies included in the meta-analysis
Study, author
Selection Comparability
 (maximum two stars)
Outcome 










Comparability of cases 
and controls on the basis 














































Star is rewarded for each item when the study presents the feature of quality. Each study can be rewarded a maximum of one star for each item 
except a maximum of two stars can be given to the item comparability. In brief, the quality criteria were defined as follows: is the case definition 
adequate: yes with independent validation; representativeness of the cases: consecutive or obviously representative series of cases; selection of con-
trols: community controls; definition of controls: no history of disease(endpoint); comparability: study controls for age and sex (1 star) and controls 
for cardiovascular risk factors (1 star); ascertainment of exposure: secure record or structured interview where blind to case/control status; same 
method of ascertainment for cases and controls: yes; non-response rate: same rate for both groups.
Advance Publication Journal of Atherosclerosis and Thrombosis 
Accepted for publication: November 18, 2019    Published online: February 15, 2020
Xia et al.
24















that outcome of 
interest was not 
present at start 
of study
Comparability of 
cohorts on the basis 





























































































Star is rewarded for each item when the study presents the feature of quality. Each study can be rewarded a maximum of one star for each item 
except a maximum of two stars can be given to the item comparability. In brief, the quality criteria were defined as follows: representativeness of the 
exposed cohort: truly or somewhat representative of the population based community; selection of the non-exposed cohort: draw from the same 
community as the exposed cohort; ascertainment of exposure: secured record or structured interview; demonstration that outcome of interest was 
not present at start of study : yes; comparability: study controls for age and sex (1 star) and controls for cardiovascular risk factors (1 star); assess-
ment of outcome: independent blind assessment or record linkage; was follow-up long enough for outcomes to occur: yes, at least 5 years; adequacy 
of follow up cohorts: complete follow up all subjects accounted for or subjects lost to follow up unlikely to introduce bias: small number (5%) lost 
follow up or description provided of those lost. 
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Supplementary Fig.1.  Funnel plots of the association between coronary artery disease and mild cognitive impairment or dementia 
in cross-sectional studies. (A), in case-control studies (B), in cohort studies that reported hazard ratio (C), 
in  cohort studies that reported odds ratio (D), and in all studies reported odds ratio (E).
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